Omeprazol Arena (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Arena, is a proton pump inhibitor (PPI) presented as a 20 mg tablet for oral use. It reduces stomach acid production and is commonly prescribed for conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Omeprazol Arena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazol Arena is a proton pump inhibitor used to manage acid‑related gastrointestinal disorders. - Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and promotes healing of the oesophageal lining. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the condition. - Helicobacter pylori eradication regimens (as part of combination therapy): enhances eradication success by maintaining a higher gastric pH. - NSA‑induced gastropathy prophylaxis: lowers the risk of ulcer formation in patients requiring chronic NSAID therapy.

Adverse reactions to Omeprazol Arena are generally mild to moderate and vary with individual sensitivity.

Common Side Effects: - Headache: mild, transient headache reported in clinical use. - Diarrhoea: loose stools occurring during initial therapy. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach region. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis linked to altered gut flora. - Acute interstitial nephritis: sudden kidney inflammation presenting with reduced urine output. - Hypomagnesemia: low serum magnesium levels causing muscle cramps or arrhythmia. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe skin reactions requiring urgent care.

When prescribing Omeprazol Arena, clinicians should consider several safety aspects. - Assess renal function: adjust use in patients with severe renal impairment. - Evaluate hepatic status: use caution in moderate to severe liver disease. - Monitor long‑term use: prolonged therapy may be associated with vitamin B12 deficiency. - Review concomitant medications: potential for altered absorption of drugs requiring acidic pH. - Pregnancy and lactation: prescribe only if the potential benefit outweighs risk. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular event risk. - Atazanavir and other protease inhibitors: markedly decreased antiviral concentrations. - Warfarin: enhanced anticoagulant effect, requiring INR monitoring.

Moderate Interactions (Monitor Closely): - Digoxin: increased serum levels, may need dose adjustment. - Methotrexate (high‑dose): reduced clearance, risk of toxicity. - Iron supplements: decreased absorption, consider timing separation. - Diazepam: elevated plasma concentrations, monitor for sedation.